Aug 2026· British Journal of Cancer· 0 citations· 36 references
Medicine
TL;DR
Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding the understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.
Abstract
Background
G protein-coupled receptors (GPCRs) are the largest class of membrane-bound receptors and are emerging as targets for the effective treatment of cancer. The role of orphan GPCR GPR52 in cancer has not been characterized. Low mRNA expression of GPR52 in breast tumours correlates with reduced overall survival, leading to the hypothesis that loss of GPR52 supports breast cancer progression.
Methods
CRISPR-Cas9 was used to knock out GPR52 in the human triple-negative breast cancer cell lines MDA-MB-468 and MDA-MB-231. 2D and 3D in vitro studies, electron microscopy, and a zebrafish xenograft model were used to assess the morphology and behaviour of GPR52 KO cells.
Results
Loss of GPR52 was associated with elevated levels of cAMP, increased cell-cell interaction in 2D cultures, more spindle-like morphology on collagen, altered 3D spheroid morphology, and increased propensity to organize and invade collectively. Zebrafish injected with GPR52 KO cells developed a greater total cancer area than control. RNA sequencing and proteomic analyses of GPR52-null cells revealed an increased cAMP signalling signature. Re-expression of GPR52 and inhibition of cAMP production rescued some GPR52 KO phenotypes.
Conclusions
GPR52 loss is a potential mechanism by which breast cancer progression may occur and supports the investigation of GPR52 agonism as a therapeutic option for breast cancer.
STATEMENT OF
Significance
Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding our understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.
GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets, and was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC.
Jihan Qiu, Cheng Tian, Hanzhi Li et al.· Frontiers in Bioscience· 0 citations
A comprehensive bioinformatic analysis of GPCR expression in endometrial cancer using publicly available RNA-sequencing data from The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA-UCEC) provides a systematic framework for understanding GPCR dysregulation and highlights candidate GPCRs for future functi...
Ece Akgun, Niamh S. Sayers, Aylin C. Hanyaloglu· European Journal of Endocrin...· 0 citations
An effective 3D co-culture system of breast cancer cells and integrated macrophages for studying dynamic cellular phenotype changes and reciprocal interactions in a heterogeneous environment to mimic aspects of the TME and enhance the accuracy of preclinical in vitro treatment response studies is presented.
Chen Cheng, Brett A. McGregor, J. Hur et al.· PLoS ONE· 0 citations
Mechanistically, EB171 induced replication stress and DNA double-strand breaks, accompanied by activation of cell cycle checkpoints, cyclin suppression, and p21Waf1/Cip1 upregulation, and these findings support further investigation of EB171 as a promising anticancer compound.
Zuzanna Rzepka, Dominika Stencel, E. Bębenek et al.· Toxicology and Applied Pharm...· 0 citations
This review summarizes current evidence on GPR65 in cancer from an immunopharmacological perspective, and discusses its molecular characteristics and proton-induced Gs-cAMP-PKA signaling, then examines tumor cell-intrinsic and immune-mediated functions, including acid-adaptive survival, macrophage polarization, CD8+ T-...
Fei Pan, Xielin Yan, Ye Chen et al.· International Immunopharmaco...· 0 citations